Home › Research › Clinical trials
UCB Presents Data on Bepranemab (anti-tau antibody) in Early Alzheimer's Disease: Phase 2a TOGETHER Study
UCB press release (data presented at CTAD 2024), 2024-10-31
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The Phase 2a TOGETHER trial tested bepranemab, an antibody targeting the tau protein (rather than amyloid), in 466 people with prodromal-to-mild Alzheimer's disease over 80 weeks. The drug did not improve the main cognitive/functional measure (CDR-SB) compared with placebo across the whole study group, but it did slow the buildup of tau seen on PET brain scans by 33-58%, with a larger tau-PET effect (63-67%) in a subgroup with lower baseline tau or without the ApoE4 gene. Side effects were similar between drug and placebo groups.
What this study adds
Evidence grade: Early
The record lists 466 participants. In the Phase 2a TOGETHER trial, the anti-tau antibody bepranemab did not improve the main cognitive/functional measure compared with placebo across the whole group, but it slowed tau buildup on PET scans by 33-58% overall. Reported effect size: Tau-PET accumulation slowed 33-58% overall, 63-67% in a lower-tau/non-ApoE4 subgroup; primary CDR-SB endpoint not met.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
UCB Presents Data on Bepranemab (anti-tau antibody) in Early Alzheimer's Disease: Phase 2a TOGETHER Study. (2024). UCB press release (data presented at CTAD 2024).
Vancouver
UCB Presents Data on Bepranemab (anti-tau antibody) in Early Alzheimer's Disease: Phase 2a TOGETHER Study. UCB press release (data presented at CTAD 2024). 2024.
BibTeX
@article{study2024-c943abc5,
title = {{UCB Presents Data on Bepranemab (anti-tau antibody) in Early Alzheimer's Disease: Phase 2a TOGETHER Study}},
journal = {UCB press release (data presented at CTAD 2024)},
year = {2024}
}
Built from the record alzhub holds for this paper, not looked up. This record has no authors, DOI, so the citation leaves them out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Phase 2a, n=466, 80-week double-blind trial of low- and high-dose bepranemab vs placebo
- Primary clinical endpoint (CDR-SB) not met in the overall population
- Tau-PET accumulation slowed by 33-58% overall and 63-67% in a lower-tau/ApoE4-non-carrier subgroup — described by researchers as the first time a tau antibody showed both a pathology and (subgroup) signal
Why it matters
In the Phase 2a TOGETHER trial, the anti-tau antibody bepranemab did not improve the main cognitive/functional measure compared with placebo across the whole group, but it slowed tau buildup on PET scans by 33-58% overall. This is a Phase 2a trial, and the clinical endpoint was not met in the overall population.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Study designphase-2-trial
- Participants466
- Effect sizeTau-PET accumulation slowed 33-58% overall, 63-67% in a lower-tau/non-ApoE4 subgroup; primary CDR-SB endpoint not met
- Evidence strengthEarly
Limitations
Primary clinical endpoint not met in the overall population; positive signal only in a subgroup; conference-presented data (CTAD 2024), not yet an independent peer-reviewed publication.
How this study scored 16/100
Press release — not a study. It scored 36 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for randomized / blinded and indexed in PubMed because the record does not state it. We have no data on times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 24 of the 66 points we could judge it on, which is 36 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 2 / 10 | Tier 4 — not a peer-reviewed journal (UCB press release (data presented at CTAD 2024)) |
| Journal's citation record | 0 / 4 | Not a journal article, so the journal's record does not count |
| Study design | 8 / 12 | A mid-stage phase 2 trial |
| Strength of evidence | 2 / 5 | Rated “early” in our summary |
| Peer-review validation | 1 / 10 | Press release — not a study. Named source is a company press release. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 466 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 24 / 66 | Scored on 12 of 20 parts. We have no data for the rest, so they are left out: 24 of the 66 points we could judge it on is 36 out of 100. |
| Total | 36 / 100 | Capped to 16 because this is not a peer-reviewed article. |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Clinical trials from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.